Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Summit Therapeutics Inc. (SMMT)

1.76   0.06 (3.53%) 03-24 16:00
Open: 1.69 Pre. Close: 1.7
High: 1.785 Low: 1.685
Volume: 951,110 Market Cap: 1,228(M)

Technical analysis

as of: 2023-03-24 4:29:57 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 2.31     One year: 2.84
Support: Support1: 1.25    Support2: 1.03
Resistance: Resistance1: 1.98    Resistance2: 2.44
Pivot: 1.6
Moving Average: MA(5): 1.68     MA(20): 1.64
MA(100): 2.52     MA(250): 1.75
MACD: MACD(12,26): -0.3     Signal(9): -0.3
Stochastic oscillator: %K(14,3): 64.6     %D(3): 54.1
RSI: RSI(14): 44.9
52-week: High: 5.78  Low: 0.66
Average Vol(K): 3-Month: 3,290 (K)  10-Days: 2,560 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ SMMT ] has closed below upper band by 20.5%. Bollinger Bands are 68.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.79 - 1.79 1.79 - 1.8
Low: 1.67 - 1.68 1.68 - 1.68
Close: 1.75 - 1.76 1.76 - 1.77

Company Description

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.

Headline News

Mon, 20 Mar 2023
INVESTIGATION ALERT: The Schall Law Firm Announces it is ... - Business Wire

Thu, 16 Mar 2023
Is Summit Therapeutics Inc (SMMT) Stock Worth a Buy Thursday? - InvestorsObserver

Mon, 13 Mar 2023
Summit Therapeutics Inc (SMMT) has fallen 2.68% Monday In Premarket Trading - InvestorsObserver

Thu, 09 Mar 2023
10 Penny Stocks with Insider Buying - Yahoo Finance

Tue, 07 Mar 2023
Premarket Mover: Summit Therapeutics Inc (SMMT) Down 2.88% - InvestorsObserver

Mon, 06 Mar 2023
Summit Therapeutics Inc (SMMT) is down 2.60% Monday In Premarket Trading - InvestorsObserver

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 211 (M)
% Held by Insiders 3.49e+007 (%)
% Held by Institutions 82.6 (%)
Shares Short 5,040 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -7.655e+007
EPS Est Next Qtl -0.63
EPS Est This Year -0.53
EPS Est Next Year -1.05
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -8
Return on Assets (ttm) 141.9
Return on Equity (ttm) -34.3
Qtrly Rev. Growth 956000
Gross Profit (p.s.) 339.45
Sales Per Share -108.06
EBITDA (p.s.) 1.96739e+006
Qtrly Earnings Growth -0.8
Operating Cash Flow 0 (M)
Levered Free Cash Flow -56 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.02
Price to Cash Flow -1.93

Stock Dividends

Dividend 0
Forward Dividend 3.91e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.